// App-Quantinova.ai

PD-8 : Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study

Researchers

Presenter

  • T. Okusaka

Principal Investigators

  • M. Kitano

  • M. Chen

  • J. Chen

  • V. Ostwal

  • M. McNamara

  • V. Breder

  • M. Petrova

  • G. Buchschacher

  • N. Rokutanda

  • J. Xiong

  • G. Cohen

  • D. Oh

Medical Centers

  • The University of Manchester, Manchester, United Kingdom

  • Wakayama Medical University, Wakayama, Japan

  • Tata Memorial Hospital, Mumbai, India

  • Kaiser Permanente Southern California, Los Angeles, United States

  • Linkou Chang-Gung Memorial Hospital and Chang-Gung University, Tao-yuan City, Taiwan

  • N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia

  • National Cancer Center Hospital, Tokyo, Japan

  • MHAT Nadezhda - Hospital for women's health, Sofia, Bulgaria

  • Seoul National University College of Medicine, Seoul, South Korea

  • Taipei Veterans General Hospital, Taipei City, Taiwan

Locations

  • United States

  • Russia

  • United Kingdom

  • Japan

  • Bulgaria

  • India

  • Republic of South Korea

  • Taiwan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

  • Extrahepatic cholangiocarcinoma

  • Gallbladder cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Durvalumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved